ERBB2 and neoplasm: Most of the patients who received chemotherapy only had basal-like (~60%) or Her2+ (~40%) tumours and, interestingly, high SETD7 was correlated with worse RFS (Figure 6B, right panels) or DMFS (not shown) only for patients with the basal-like subtype.